$AQU
Aquaron Acquisition Corp.

2023 Q2 Form 10-Q Financial Statement

#000121390023039838 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $100.00
YoY Change
Gross Profit -$100.00
YoY Change
Gross Profit Margin
Selling, General & Admin $270.0K $350.0K $210.0K
YoY Change 2600.0%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $270.0K $350.0K $210.0K
YoY Change 2600.0%
Operating Profit -$272.6K -$352.8K -$210.1K
YoY Change 5322.08% 16365.05%
Interest Expense $670.0K $590.0K $440.0K
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income $390.0K $240.0K $220.0K
YoY Change -4000.0%
Income Tax $210.5K $46.59K $50.00K
% Of Pretax Income 53.98% 19.41% 22.73%
Net Earnings $311.1K $151.8K $170.0K
YoY Change -6288.6% -7183.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.04 $0.02 $0.02
COMMON SHARES
Basic Shares Outstanding 7.040M shares 7.040M shares 7.040M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $56.83M $56.03M $55.48M
YoY Change 189344.93% 93289.05% 277292.57%
Cash & Equivalents $65.63K $37.25K $57.28K
Short-Term Investments $56.77M $56.00M $55.42M
Other Short-Term Assets $240.0K $220.0K $220.0K
YoY Change -14.29% -15.38% -12.0%
Inventory
Prepaid Expenses $146.9K $222.1K $222.3K
Receivables
Other Receivables
Total Short-Term Assets $57.07M $56.26M $55.70M
YoY Change 18309.82% 17479.86% 20618.65%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $57.07M $56.26M $55.70M
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $57.07M $56.26M $55.70M
YoY Change 18309.82% 17479.86% 20618.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $200.0K $220.0K $140.0K
YoY Change 180.0%
Accrued Expenses $20.00K $10.00K $10.00K
YoY Change -79.14%
Deferred Revenue
YoY Change
Short-Term Debt $760.0K $240.0K $0.00
YoY Change 153.33% -20.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $29.94M $3.234M $2.831M
YoY Change 9880.19% 977.85% 1040.29%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $29.94M $3.234M $2.831M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $29.94M $3.234M $2.831M
YoY Change 9880.19% 977.85% 1040.29%
SHAREHOLDERS EQUITY
Retained Earnings -$3.457M $311.5K $159.7K
YoY Change -3732.21%
Common Stock $163.00 $163.00 $163.00
YoY Change 13.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 5.000M shares
Shareholders Equity -$3.457M $1.315M $5.299M
YoY Change
Total Liabilities & Shareholders Equity $57.07M $56.26M $55.70M
YoY Change 18309.82% 17479.86% 20618.65%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q4
OPERATING ACTIVITIES
Net Income $311.1K $151.8K $170.0K
YoY Change -6288.6% -7183.81%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$210.0K -$273.1K -$280.0K
YoY Change 250.0% 11079.74%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $110.0K $10.00K -$54.98M
YoY Change
Cash From Investing Activities $110.0K $13.09K -$54.98M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 130.0K $240.0K 55.31M
YoY Change -533.33% 444.7% -184466.67%
NET CHANGE
Cash From Operating Activities -210.0K -$273.1K -280.0K
Cash From Investing Activities 110.0K $13.09K -54.98M
Cash From Financing Activities 130.0K $240.0K 55.31M
Net Change In Cash 30.00K -$20.04K 50.00K
YoY Change -133.33% -148.14% -266.67%
FREE CASH FLOW
Cash From Operating Activities -$210.0K -$273.1K -$280.0K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41470
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
86-2760193
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
515 Madison Avenue
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
8th Floor
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10022
CY2023Q1 dei City Area Code
CityAreaCode
(646)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
970 2181
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7040240 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37249 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
57284 usd
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
222125 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
222346 usd
CY2023Q1 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
55996181 usd
CY2022Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
55421229 usd
CY2023Q1 us-gaap Assets Current
AssetsCurrent
56255555 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
55700859 usd
CY2023Q1 us-gaap Assets
Assets
56255555 usd
CY2022Q4 us-gaap Assets
Assets
55700859 usd
CY2023Q1 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
99846 usd
CY2022Q4 us-gaap Other Accounts Payable And Accrued Liabilities
OtherAccountsPayableAndAccruedLiabilities
99846 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220666 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
140075 usd
CY2023Q1 aqu Franchise Tax Payable
FranchiseTaxPayable
12000 usd
CY2022Q4 aqu Franchise Tax Payable
FranchiseTaxPayable
13086 usd
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
98339 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
51753 usd
CY2023Q1 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
36799 usd
CY2023Q1 aqu Promissory Note Related Party
PromissoryNoteRelatedParty
240000 usd
CY2023Q1 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2525896 usd
CY2022Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2525896 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
3233546 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2830656 usd
CY2023Q1 us-gaap Liabilities
Liabilities
3233546 usd
CY2022Q4 us-gaap Liabilities
Liabilities
2830656 usd
CY2023Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
0.0001
CY2023Q1 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
10000000 shares
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5417180 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
5417180 shares
CY2023Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5417180 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
5417180 shares
CY2023Q1 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
51706675 usd
CY2022Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
47571463 usd
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
163 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
163 usd
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1003693 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5138905 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
311478 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
159672 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1315334 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5298740 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56255555 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55700859 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
340846 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2143 usd
CY2023Q1 us-gaap Franchisor Costs
FranchisorCosts
12000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-352846 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2143 usd
CY2023Q1 us-gaap Interest Income Securities Other Us Government
InterestIncomeSecuritiesOtherUSGovernment
375656 usd
CY2023Q1 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
212381 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
235191 usd
CY2022Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-2143 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
46586 usd
CY2023Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
36799 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
151806 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2143 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
5298740 usd
CY2023Q1 aqu Stock Issued During Period Value Accretion Of Common Stock To Redemption Value
StockIssuedDuringPeriodValueAccretionOfCommonStockToRedemptionValue
-4135212 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
151806 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1315334 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
20604 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2143 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
18461 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
151806 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2143 usd
CY2023Q1 aqu Increase Decrease In Interest Earned On Investment Held In Trust Account
IncreaseDecreaseInInterestEarnedOnInvestmentHeldInTrustAccount
375656 usd
CY2023Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
212381 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-221 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
80590 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-300 usd
CY2023Q1 us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
-1086 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
46586 usd
CY2023Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
36799 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-273121 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2443 usd
CY2023Q1 us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
13086 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13086 usd
CY2023Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
240000 usd
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100000 usd
CY2022Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
55939 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
240000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44061 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-20035 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
41618 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57284 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16860 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37249 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
58478 usd
CY2023Q1 aqu Accretion Of Common Stock To Redemption Value
AccretionOfCommonStockToRedemptionValue
4135212 usd
CY2022Q4 us-gaap Investment Unrestricted Purchase Price Date Per Unit
InvestmentUnrestrictedPurchasePriceDatePerUnit
10
CY2023Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
750000 shares
CY2022Q4 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2022Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Investing Activities
SaleLeasebackTransactionGrossProceedsInvestingActivities
4171800 usd
CY2022Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Financing Activities
SaleLeasebackTransactionGrossProceedsFinancingActivities
125154 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5000001 usd
CY2023Q1 us-gaap Taxes Payable Current And Noncurrent
TaxesPayableCurrentAndNoncurrent
50000 usd
CY2023Q1 aqu Trust Account Per Share
TrustAccountPerShare
10.15
CY2023Q1 us-gaap Equity Fair Value Disclosure
EquityFairValueDisclosure
1200000000 usd
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
10
CY2023Q1 us-gaap Investments And Cash
InvestmentsAndCash
37249 usd
CY2023Q1 us-gaap Capital Units
CapitalUnits
301138 usd
CY2023Q1 us-gaap Line Of Credit Facility Periodic Payment
LineOfCreditFacilityPeriodicPayment
25000 usd
CY2023Q1 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
300000 usd
CY2023Q1 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
140000 usd
CY2023Q1 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
130000 usd
CY2022Q3 us-gaap Derivative Average Forward Interest Rate
DerivativeAverageForwardInterestRate
0.01 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Other
EffectiveIncomeTaxRateReconciliationTaxCreditsOther
0.01 pure
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In preparing these unaudited financial statements in conformity with U.S. GAAP, the Company’s management makes estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported expenses during the reporting period.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q1 us-gaap Cash
Cash
37249 usd
CY2022Q4 us-gaap Cash
Cash
57284 usd
CY2023Q1 us-gaap Assets Held In Trust
AssetsHeldInTrust
55996181 usd
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
55421229 usd
CY2023Q1 aqu Interests Earned
InterestsEarned
588037 usd
CY2023Q1 us-gaap Deferred Policy Acquisition Costs Text Block1
DeferredPolicyAcquisitionCostsTextBlock1
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deferred Offering Costs</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company complies with the requirements of Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (the “ASC”) Topic 340-10-S99-1, “Other Assets and Deferred Costs – SEC Materials” and SEC Staff Accounting Bulletin Topic 5A, “Expenses of Offering”. Offering costs are allocated between public shares and public rights based on the estimated fair values of public shares and public rights at the date of issuance. Deferred offering costs consisted principally of underwriting, legal, accounting and other expenses were charged to stockholders’ equity upon the completion of the IPO on October 6, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.3545 pure
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q1 us-gaap Net Income Loss Allocated To Limited Partners
NetIncomeLossAllocatedToLimitedPartners
-151806 usd
CY2022Q1 us-gaap Net Income Loss Allocated To Limited Partners
NetIncomeLossAllocatedToLimitedPartners
2143 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4135212 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-3983406 usd
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-2143 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentration of Credit Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $250,000. As of March 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1 us-gaap Federal Deposit Insurance Corporation Premium Expense
FederalDepositInsuranceCorporationPremiumExpense
250000 usd
CY2023Q1 aqu Common Stock Subject To Possible Redemption
CommonStockSubjectToPossibleRedemption
4135212 usd
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
54171800 usd
CY2022 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
6446444 usd
CY2022 aqu Allocation Of Offering Costs Related To Redeemable Shares
AllocationOfOfferingCostsRelatedToRedeemableShares
-3714253 usd
CY2022 aqu Accretion Of Carrying Value To Redemption Value
AccretionOfCarryingValueToRedemptionValue
3560360 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
47571463 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
4135212 usd
CY2023Q1 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
51706675 usd
CY2022Q4 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
5000000 shares
CY2022Q4 us-gaap Share Price
SharePrice
10
CY2022Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
10
CY2022Q4 aqu Proceed From Issuance Initial Public Offering
ProceedFromIssuanceInitialPublicOffering
125154 usd
CY2021Q2 aqu Aggregate Price
AggregatePrice
25000 usd
CY2021Q2 aqu Share Issued And Outstanding Percentage
ShareIssuedAndOutstandingPercentage
0.20 pure
CY2023Q1 aqu Subject To Certain Limited Exceptions Percentage
SubjectToCertainLimitedExceptionsPercentage
0.50 pure
CY2022Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
200000 usd
CY2022Q4 us-gaap Repayments Of Debt
RepaymentsOfDebt
100000 usd
CY2023Q1 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
240000 usd
CY2022 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
0 usd
CY2023Q1 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
99846 usd
CY2021Q1 us-gaap Related Party Tax Expense Due To Affiliates Deferred
RelatedPartyTaxExpenseDueToAffiliatesDeferred
99846 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
750000 shares
CY2023Q1 us-gaap Other Underwriting Expense
OtherUnderwritingExpense
812577 usd
CY2023Q1 aqu Gross Proceeds
GrossProceeds
1896013 usd
CY2022Q4 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
100 usd
CY2022Q4 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
97509 shares
CY2022Q4 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
11.5
CY2022Q4 us-gaap Percentage Of Weighted Average Cost Inventory
PercentageOfWeightedAverageCostInventory
1.15 pure
CY2023Q1 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
10000000 shares
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0.0001
CY2023Q1 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Holders of the common stock are entitled to one vote for each share
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
187500 shares
aqu Initial Stockholders Percentage
InitialStockholdersPercentage
0.20 pure
CY2022Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
187500 shares
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
1623060 shares
CY2023Q1 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
1623060 shares
CY2023Q1 aqu Subject To Possible Redemption
SubjectToPossibleRedemption
5417180 shares
CY2023Q1 us-gaap Marketable Securities
MarketableSecurities
55996181 usd
CY2022Q4 us-gaap Marketable Securities
MarketableSecurities
55421229 usd
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Aquaron Acquisition Corp.
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
usd
CY2022Q1 aqu Increase Decrease In Interest Earned On Investment Held In Trust Account
IncreaseDecreaseInInterestEarnedOnInvestmentHeldInTrustAccount
usd
CY2022Q1 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
usd
CY2022Q1 us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
usd
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
CY2022Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
CY2022Q1 us-gaap Proceeds From Decommissioning Fund
ProceedsFromDecommissioningFund
usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2022Q1 aqu Accretion Of Common Stock To Redemption Value
AccretionOfCommonStockToRedemptionValue
usd
CY2023Q1 us-gaap Other Loans Payable Current
OtherLoansPayableCurrent
10000 usd
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
usd
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001861063

Files In Submission

Name View Source Status
aqu-20230331_cal.xml Edgar Link unprocessable
0001213900-23-039838-index-headers.html Edgar Link pending
0001213900-23-039838-index.html Edgar Link pending
0001213900-23-039838.txt Edgar Link pending
0001213900-23-039838-xbrl.zip Edgar Link pending
aqu-20230331.xsd Edgar Link pending
f10q0323ex31-1_aquaronacq.htm Edgar Link pending
f10q0323ex31-2_aquaronacq.htm Edgar Link pending
f10q0323ex32-1_aquaronacq.htm Edgar Link pending
f10q0323ex32-2_aquaronacq.htm Edgar Link pending
f10q0323_aquaronacq.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
aqu-20230331_def.xml Edgar Link unprocessable
aqu-20230331_lab.xml Edgar Link unprocessable
aqu-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0323_aquaronacq_htm.xml Edgar Link completed
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending